On December 20, 2012, Cao, Sheldon; Popovici-Muller, Janeta; Salituro, Francesco G.; Saunders, Jeffrey; Tan, Xuefei; Travins, Jeremy; Yan, Shunqi; Ye, Zhixiong published a patent.Reference of 5-Chloroquinoxaline The title of the patent was Pyridinyl-heterocycles as isocitrate dehydrogenase 1 inhibitors and their preparation, therapeutically active compositions and their methods of use. And the patent contained the following:
Provided are compounds of formula I. pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds Compounds of formula I wherein Y is NR5, NR5CH2, CH2NR5 and CHR5; m is 0, 1, 2 and 3; R1a and R1b are independently H, C1-4 alkyl, heterocyclyl, etc.; R2 is (un)substituted Ph, (un)substituted 3- to 7-membered cycloalkyl, C2-4 alkyl and CF3; each R3 is independently halo,C1-4 fluoroalkyl, Ph, heteroaryl, etc.; R4 is H, CN, halo, C1-4 alkoxy, etc.; R5 is alkanoyl, alkenoyl, sulfonyl, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their IDH1 R132H inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value in the range of > 1 μM and ≤ 5 μM. The experimental process involved the reaction of 5-Chloroquinoxaline(cas: 62163-09-1).Reference of 5-Chloroquinoxaline
The Article related to pyridinyl heterocycle preparation idh1 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Diazepines and other aspects.Reference of 5-Chloroquinoxaline
Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider